2024 Poster Presentations
P01: PELETAC: A Computational Workflow to Model Protacs Ternary Complex Landscape, Presented by Anna Maria DR., Barcelona Supercomputing Center
P02: Generative Strategies for Multi-Target Drug Design: Generating Coronaviruses Pan-Inhibitors, Presented by Julia VM., Barcelona Supercomputing Center
P03: QM4Bio: Quantum Mechanics for Protein-Ligand Interactions, Presented by Benjamin M., BASF SE
P04: Deep Characterization of Binding Kinetics for 210 Kinase Inhibitors Against 80+ Kinases, Presented by Andrew G., Carterra, Inc.
P05: PROTAC: A Tool for Validating Retro-2 Protein Target, Presented by Marine M., CEA - French Alternative Energies and Atomic Energy Commission
P06: Affinity Selection Mass Spectrometry in Hit-Identification, Presented by Didier R., Edelris
P07: In-Cell Proximity Target Validation Methods for PROTACs Based on CRBN- or VHL-Binder Using Proximity Labeling Enzyme AirID, Presented by Kohdai Y., Ehime University
P08: Deep Learning for Drug Discovering the Needle in Microbial Natural Product Extract Libraries: Positive Precision Approaches, Presented by Ruben T., Fundacion MEDINA
P09: Resolving Fine Structure and Dynamics for Drug Discovery Using EPR Spectroscopy, Presented by Austin GJ., High Q Technologies
P10: Discovery of Highly Potent SARS-CoV-2 nsp14 Methyltransferase Inhibitors Based on Adenosine 5'-Carboxamides, Presented by Hugo K., Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
P11: Unlocking the Secrets of Orthonairoviral Endonucleases: Synthesis and Evaluation of Innovative Heterocyclic Inhibitors, Presented by Robert R., Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
P12: Destruction of Toxic Protein Aggregates: Investigation NRF1 Activators Affecting Proteasome Activity and Preventing Protein Aggregation, Presented by Lucie S., Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
P13: Developing Molecular Glues to Target KRAS in Cancer, Presented by Hanne P., KU Leuven
P14: Novel Covalent Inhibitors for Drug Discovery, Presented by Anna Z., Life Chemicals Europe GmbH
P15: Purchasable Building Blocks Suitable for DEL Chemistry Curated from the Mcule Database, Presented by Bence B., Mcule.com Kft.
P16: Enhancing Degrader Research: CETSA as a Tool for Assessing Selectivity of Warheads and PROTACS and for Detecting Binders that Remain Intact, Presented by Isabel M., Pelago Bioscience AB
P17: Enabling Novel Live Cell Assays with a Silicon Membrane-Based Platform for Mechanical Delivery of Impermeable Small Molecules, Peptides, and Probes to Accelerate Early Drug Discovery, Presented by Crystal T., Portal Biotechnologies
P18: AI/ML-Methodology for Prediction and Optimization Human Pharmacokinetics Outperforms Laboratory Methods, Presented by Urban F., PROSILICO
P19: Quantum Computing in Drug Discovery with FMO-HiVQE Methodology to Elucidate Inter-Molecular Interactions, Presented by Eleni M., Qunova Computing, Inc..
P20: Identifying Novel CDK9 Inhibitors by Traditional Virtual Screening and AI-Based Approaches, Presented by Kyryl P., Red Glead Discovery
P21: Discovery of Novel Ligase Ligands Using Affinity Selection Mass Spectrometry (ASMS), Presented by Andrew N., Sygnature Discovery Ltd.
P22: Identification of BETAC-1, a Novel BRD4 Bifunctional Degrader, Accelerated by Viva Biotech’s TPD Discovery Platform, Presented by Robin W., SYNthesis Med Chem
P23: Discovery of Novel 1-Aminophthalazine Derivatives as Potent, Selective, Orally Available, and Brain Penetrable C1s Inhibitors for Modulation of the Complement Pathway, Presented by Zenichi I., Takeda Pharmaceutical Company Ltd.
P24: Targeting the ESCRT Machinery: A Promising Strategy for the Development of Novel Broad-Spectrum Antivirals (BSAs), Presented by Daniele R., Università degli Studi di Parma
P25: Design and Synthesis of Azaborine-Based HDAC-Inhibitors, Presented by Martin B., University of Applied Sciences Darmstadt
P26: Ligand-First vs. Electrophile-First Approaches to Target His and Lys with Aryl-Fluorosulfates: Applications to hMcl-1, Presented by Giulia A., University of California, Riverside
P27: Development of TROP-2-Targeting Degrader-Antibody Conjugates for Triple-Negative Breast Cancer, Presented by Frederico AS., University of Lisbon
P28: Computer-Based Design and Development of CM-444 Targeted Protein Degraders Against Epigenetic Factors in Multiple Myeloma, Presented by Inigo AZ., University of Navarra
P29: Unlocking the Potential of Inhibitors for Future Pandemics: Targeting the Main Protease of SARS-CoV-2, Presented by Marie Jose AS., University of Vienna
P30: DELs in Cells: Direct Screening of DNA Encoded Libraries for PPI Inhibitors, Presented by Leif L., Vipergen Aps
P31: Cell-Based Strategies to Accelerate Small-Molecule Drug Discovery, Presented by Seher A., Karolinska Institutet
P32: Overcoming Metallo-Beta-Lactamase Driven Antibiotic Resistance with a Codrug Approach, Presented by Nauris N., Latvian Institute of Organic Synthesis
P33: A Novel NMR-Based Protocol to Screen Ultralow Molecular Weight Fragments, Presented by Annagiulia F., Università di Padova (University of Padua)
P34: iScore: An ML-Based Rapid Scoring Function for de novo Drug Discovery, Presented by Leif E., ANYO Labs
P35: The Quest for Ligands Against Kinesin Motor Proteins Using CADD, Presented by Ahmet S., Bezmialem Vakif University
P36: Evaluation of the Cytotoxicity Activity of Andrographolide in Combination with Sorafenib Against Liver Cancer Cells, Presented by Thikryat N., King Abdulaziz University
P37: Development and Characterization of GelMA Hydrogel Containing Temozolomide and YAP siRNA Loaded in Trimethyl Chitosan-Hyaluronate Nanoparticles for Localized Drug Delivery to Glioblastoma Tumors, Presented by Aryan F., Tehran University of Medical Sciences
P38: Design, Synthesize, and Evaluate a New, Less Cytotoxic Progesterone-Derived Oral Contraceptive. Designed by Ligand and Structure-Based Virtual Screening, Presented by James G., Univeridad El Bosque